JJJinjiang Jiang

Jinjiang Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinjiang Jiang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Urinary heavy metal burden and overactive bladder risk: a cross-sectional study based on NHANES 2005–2018

    by Jinbao Wang, Qiyou Wu, Bo Chen, Jinze Li, Jinjiang Jiang, Xinyang Liao, Qiang Wei

    Objective: We aimed to explore the relationship between urinary heavy metals and overactive bladder (OAB) among US adults. Method: Data were obtained from the National Health and Nutrition Examination Survey 2005–2018. Concentrations of heavy metals in urine were determined by laboratory tests and corrected for urinary creatinine using natural logarithm (ln) transformation. OAB was assessed using questionnaires. The association between each urinary heavy metal and OAB was first explored using multivariate logistic regression, followed by nonlinear correlation analyses and smoothed curve fitting, with stratified analyses and interaction tests for age and sex. In addition, weighted quantile sum (WQS) regression and quantile-based g-computation (qgcomp) analyses were implemented to explore the relationship between mixed heavy metal and OAB. Results: A total of 9086 participants were included in the final study. Multifactorial logistic regression analysis showed that cobalt (Co), lead (Pb), cadmium (Cd), and uranium (Ur) were positively associated with the risk of developing OAB, whereas barium (Ba) and thallium (Tl) were negatively associated with OAB. Nonlinear correlation analysis showed that the associations between the concentrations of Ba and Tl and OAB risk were nonlinear, and Pb, antimony (Sb), tungsten (Tu), Ur, and Cd showed significant positive correlations with OAB. WQS regression showed that OAB risk increased with increasing quartiles of the WQS index [odds ratio (OR) 1.202, 95% confidence interval (CI) 1.064–1.357], with Cd showing the strongest positive correlation with OAB. When the mixture effect was constrained to be negative, an increase in the WQS index quartile corresponded to a 14.3% reduction in OAB risk (OR 0.857, 95% CI 0.778–0.943), with Ba standing out as the most dominant. The results of qgcomp analysis showed that Cd had the largest positive weight of 0.5098, and Ba had the largest negative weight of 0.5976. Conclusion: Urinary heavy metals are significantly associated with OAB risk among US adults. The metal contributing most to the positive correlation with OAB risk is Cd, while the metal contributing most to the negative correlation with OAB risk is Ba.


  • Open Access

    Selenium in Prostate Cancer: Prevention, Progression, and Treatment

    by Jinjiang Jiang, Bo Chen, Bo Tang, Qiang Wei

    Selenium, a trace mineral with various biological functions, has become a focal point in prostate cancer research. This review aims to present a comprehensive overview of selenium’s involvement in prostate cancer, covering its impact on prevention, development, treatment, and underlying mechanisms. Observational studies have revealed a link between selenium levels and selenoproteins with prostate cancer progression. However, randomized controlled studies have shown that selenium supplementation does not prevent prostate cancer (HR: 0.95; 95% CI 0.80–1.13). This discrepancy might be attributed to selenoprotein single nucleotide polymorphisms. In the context of combinatorial therapy, selenium has demonstrated promising synergistic potential in the treatment of prostate cancer. Emerging evidence highlights the significant role of selenium and selenoproteins in prostate cancer, encompassing AR signaling, antioxidative properties, cell death, cell cycle regulation, angiogenesis, epigenetic regulation, immunoregulation, epithelial–mesenchymal transformation, and redox signal. In conclusion, selenium’s diverse properties make it a promising trace mineral in prostate cancer prevention, development, and treatment and as a platform for exploring novel agents.


  • Open Access

    The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis

    by Bo Chen, Jinze Li, Yin Huang, Bo Tang, Jinjiang Jiang, Zeyu Chen, Jin Li, Puze Wang, Dehong Cao, Liangren Liu, et al.

    Background: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial. In addition, several unanswered questions regarding the use of CN remain: Can CN provide survival benefits for patients with mRCC? Where do we place CN in the treatment sequence paradigm among patients with mRCC? How do we best stratify patients with mRCC for CN therapy? Materials and Methods: A search strategy was conducted in the PubMed, Embase, and Web of Science databases. Studies were included only in the English language. The risk of bias assessment was made by using ROBINS-I (Risk of Bias in Nonrandomized Studies of Interventions) and RoB 2 (Risk of Bias 2) tools. The expected outcomes were analyzed by meta-analyses with the fixed-effects model or random effects model, including overall survival (OS) and progression-free survival (PFS). The measure of effect was the hazard ratio (HR) with a 95% CI, and sensitivity analysis was conducted to assess the reliability of the final results. Results: A total of 30 studies were included in the qualitative analysis. The HR for OS was 0.55 (95% CI, 0.50–0.61), and PFS was 0.72 (95% CI, 0.66–0.80), favoring CN compared with no CN. The upfront CN plus targeted therapy (TT) group had superior OS (HR, 0.57; 95% CI, 0.51–0.64) compared with the TT alone group. Furthermore, upfront CN plus systemic therapy (ST) was associated with numerically inferior OS compared with ST plus deferred CN in patients with mRCC (HR, 1.31; 95% CI, 0.98–1.74). Finally, the leave-one-out test of sensitivity analysis indicated that the results of this meta-analysis were stable and reliable in the overall HR estimates for these survival outcomes. Conclusions: First, CN was associated with better survival than no CN in patients with mRCC. Second, the combination of upfront CN and TT may lead to superior survival outcomes compared to TT alone in patients with mRCC. Survival outcomes were similar between the upfront CN+ST group and the ST+deferred CN group in patients with mRCC. Exact patient selection based on baseline prognostic factors is needed to promise maximal survival for patients with mRCC.


  • Open Access

    Prognostic Utility of the Modified Glasgow Prognostic Score in Urothelial Carcinoma: Outcomes from a Pooled Analysis

    by Daqing Tan, Jinze Li, Tianhai Lin, Ping Tan, Jiapeng Zhang, Qiao Xiong, Jinjiang Jiang, Yifan Li, Peng Zhang, Qiang Wei

    Background: Many studies explored the prognostic value of the modified Glasgow Prognostic Score (mGPS) in urothelial carcinoma (UC), but the results are controversial. This study aimed to quantify the relationship between pretreatment mGPS and survival in patients with UC. Methods: A systematic literature search was conducted using Embase, PubMed, and Web of Science to identify eligible studies published before August 2022. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between pretreatment mGPS and the prognosis of UC. Results: Thirteen eligible studies involving 12,524 patients were included. A high mGPS was significantly associated with poor overall survival (mGPS 1/0: HR = 1.33, 95% CI 1.12–1.58, p = 0.001; mGPS 2/0: HR = 2.02, 95% CI 1.43–2.84, p < 0.0001), progression-free survival (mGPS 1/0: HR = 1.26, 95% CI 1.03–1.53, p = 0.021; mGPS 2/0: HR = 1.76, 95% CI 1.12–2.77, p = 0.013), recurrence-free survival (mGPS 1/0: HR = 1.36, 95% CI 1.18–1.56, p < 0.0001; mGPS 2/0: HR = 1.70, 95% CI 1.44–2.000, p < 0.0001), and cancer-specific survival (mGPS 2/0: HR = 1.81, 95% CI 1.30–2.52, p < 0.0001). A subgroup analysis of OS also yielded similar results. Conclusions: Evidence suggests that high pretreatment mGPS in UC is closely related to poor survival. Pre-treatment mGPS is a powerful independent prognostic factor in patients with UC.